EVENT | BOS BASEL

BOS Basel 2024's scope is primarily development-stage CMC outsourcing for both Small Molecules and Biologics, as well as covering Novel Therapeutic Entities.

BOS Basel 2024's scope is primarily development-stage CMC outsourcing for both Small Molecules and Biologics, as well as covering Novel Therapeutic Entities.
June 12, 2024
|

Asphalion is excited to be part of the BOS Basel 2024 event, a nexus for expertise, innovation, and strategic collaboration across the complete pharmaceutical life-cycle. We cordially invite all CMC professionals from  CDMOs and pharmaceutical companies to join us at our Booth 44 for an enriching exchange of insights and potential collaborations.

Why Visit us?

  • End-to-End Life-Cycle Support: Learn about our comprehensive end-to-end support through each phase of the drug development process, from early-stage development to post-marketing surveillance.
  • Tailored CMC Solutions: Discover how our bespoke services can streamline your CMC strategy and operations, aligning with regulatory compliance and industry best practices.
  • Expert Insights: Engage with our team of seasoned experts who bring in-depth knowledge and experience across the entire CMC lifecycle, ensuring thorough understanding and support for your specific needs.
  • Networking Opportunities: Connect with peers, discuss industry trends, and explore synergies in a collaborative environment.
  • Future Partnerships: Let’s discuss how we can support each other’s goals through strategic partnerships and collaborative efforts.

 

We are looking forward to discussing how Asphalion can support and enhance your CMC activities, ensuring success in your projects and regulatory endeavors. With our end-to-end support, we are dedicated to assisting you throughout the drug life-cycle, from concept to commercialization and beyond.

Please feel free to schedule a meeting with us in advance or simply drop by our booth at your convenience. Contact us at: [email protected]

 

Event Info

a

Search News & Events

  • Filter by category

Share

Related news and events

NEWS | FDA draft guidance on FAQs

The FDA issued a draft guidance on November 18 titled “Frequently Asked Questions: Developing Potential Cellular and Gene Therapy Products.” This guidance aims to assist

NEWS | Update from FDA

This guidance is intended for holders of Type II active pharmaceutical ingredient (API) drug master files (DMFs) that will be referenced in an abbreviated new drug application (ANDA), or a prior approval supplement (PAS) to an ANDA. This guidance explains how FDA incorporates a program enhancement agreed upon by the Agency and industry as part of the negotiations relating to reauthorization of the Generic Drug User Fee Amendments (GDUFA), as described in “GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023- 2027” (GDUFA III commitment letter). Specifically, this guidance describes instances when an early assessment or “DMF prior assessment,” could be requested by a DMF holder and the circumstances under which FDA would commence an early assessment of Type II API DMFs 6 months prior to an ANDA or PAS submission referencing the DMF. It also provides recommendations for such DMF holders when making a request. The guidance does not apply to Type II API DMFs used to support new drug applications (NDAs), submissions related to ANDAs that are not described above, or any other types of DMFs.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting